Connect with us


Pampa Hemp Introduces First Medical Cannabis Seed Developed and Produced in Argentina

Argentina has been developing its cannabis production chain in recent years, promoting medical and scientific research on the medicinal use of the plant and its derivatives, as well as its industrial use. Pampa Hemp has recently been able to develop and produce the first medical cannabis seed in Argentina. The news will benefit the whole cannabis industry in the country.



Pampa Hemp, an Argentinean SME dedicated to the research, development, and production of cannabis for medicinal purposes, announces a historic achievement in the country with the approval of its first native cannabis seed variety, PH LOBERA, by the National Seed Institute (INASE).

Read more about Pampa Hemp and find the latest cannabis news with the mobile app.

This scientific breakthrough achieved by Pampa Hemp is important for the entire cannabis industry, as it eliminates the need to import seeds

After more than several years of research and development work, this new seed variety has been approved and is now part of Argentina’s National Cultivar Registry. Authorized local producers and people registered in the Reprocann (National Registry of Patients in Treatment with Cannabis) can now acquire the seed and obtain better results thanks to its ability to better adapt to the climatic conditions of the region. In addition, this scientific breakthrough is important for the entire cannabis industry, as it eliminates the need to import seeds.

“Our goal was to create a variety that has excellent adaptation to the soil, climate, and resistance to the pests that exist in the Province of Buenos Aires for outdoor cannabis crops. It also has a high concentration of THC and CBG, the latter a cannabinoid that is not so easy to find and is being increasingly observed for the therapeutic benefits it offers as an anti-inflammatory and pain reliever. We are currently working on genotyping tasks and molecular markers that will allow us to continue with the photo-improvement work,” explained Sebastian Tedesco, Technical Director and Co-Founder of Pampa Hemp.

This development began as an idea in 2017, with different tests being carried out by Pampa Hemp in a field in Lobos with various seed varieties to find the one that would best adapt to the soil and coexist better with native plant species. This process was the kick that led to the creation of a new strain that is now available on the market.

The registration of PH LOBERA in the registry is one more step towards the consolidation of the cannabis sector in Argentina, which seeks to promote medical and scientific research, as well as the industrial development of the crop. The official recognition of this strain will contribute to the growth of the cannabis production chain and to the strengthening of Argentina’s position in the global market of hemp and cannabis products.

The legal framework for cannabis in Argentina

Argentina has been developing its cannabis production chain in recent years, promoting medical and scientific research on the medicinal use of the plant and its derivatives, as well as its industrial use.

Law No. 27,350 and its regulatory decree No. 883 dated November 11th, 2020, establish the regulatory framework for the research and medicinal use of cannabis, while Law No. 27,669 regulates the production and commercialization of the plant, its seeds, and derived products for medicinal and industrial use.

Within the framework of these laws, the joint resolution between the National Ministry of Health and INASE authorized the registration of Cannabis sativa L. cultivars in the National Register of Cultivars. The purpose of registering varieties in INASE is to comply with the legal requirements so that cannabis users registered in the Reprocann can have access to national seeds with traceability and identity, and that there is material available for production projects approved by the Ministry of Health.


(Featured image by CBD-Infos-com via Pixabay)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in El Economista, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Helene Lindbergh is a published author with books about entrepreneurship and investing for dummies. An advocate for financial literacy, she is also a sought-after keynote speaker for female empowerment. Her special focus is on small, independent businesses who eventually achieve financial independence. Helene is currently working on two projects—a bio compilation of women braving the world of banking, finance, crypto, tech, and AI, as well as a paper on gendered contributions in the rapidly growing healthcare market, specifically medicinal cannabis.